PT - JOURNAL ARTICLE AU - Fan, Huaxin AU - Kuang, Nanyu AU - Wu, Xinran AU - Yu, Gechang AU - Jia, Tianye AU - Sahakian, Barbara J. AU - Robbins, Trevor W. AU - Schumann, Gunter AU - Feng, Jianfeng AU - Becker, Benjamin AU - Zhang, Jie TI - Anxiety-impulsivity subtypes in adolescent internalizing disorder are characterized by distinguishable neurodevelopmental, neurocognitive and clinical trajectory signatures AID - 10.1101/2021.10.30.21265692 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.30.21265692 4099 - http://medrxiv.org/content/early/2021/10/30/2021.10.30.21265692.short 4100 - http://medrxiv.org/content/early/2021/10/30/2021.10.30.21265692.full AB - Background Anxiety and impulsivity represent transdiagnostic pathology dimensions yet their interaction and contribution to emotional disorders in adolescence and to disease development remain controversial, and previous studies indicate heterogeneity within the broad category of internalizing disorders.Methods A combination of hierarchical and non-hierarchical clustering strategies was employed to determine impulsivity-related subtypes (based on the facets of negative urgency, lack of planning, lack of perseverance, sensation seeking and positive urgency in UPPS-P scales) in a large cohort of adolescents with internalizing disorders (n=2437) from Adolescent Brain Cognitive Development (ABCD) Study. Linear mixed-effect models were employed to determine cortical thickness alterations of the subtypes.Results Data-driven clustering identified two distinct subtypes of internalizing patients (subtype 1/subtype 2) with comparable levels of increased anxiety yet distinguishable levels of impulsivity, i.e., enhanced (subtype 1) or decreased (subtype 2) compared to healthy controls. Subtype 1 was further characterized by thicker prefrontal and temporal cortical regions involved in regulatory control and fear processing, while subtype 2 did not demonstrate significant thickness alterations. The differential neuroanatomical profiles remained stable over the two-year follow-up, while the two subtypes had different neurodevelopmental trajectories. Subtype 1 additionally reported more psychopathology and dysfunctionality including higher suicidal ideation, depressive symptoms and transition rates to externalizing disorders during follow-up as well as impaired neurocognitive and educational performance compared to subtype 2. Moreover, for subtype 1, anxiety at baseline (9-10 years) was significantly positively associated with impulsivity (lack of perseverance) at 2-year follow-up, while in subtype 2, baseline anxiety was significantly negatively associated with impulsivity (sensation seeking) at 2-year follow-up.Conclusions Our results demonstrate an impulsivity-dependent heterogeneity in adolescent internalizing disorders, with high-impulsivity patients being characterized by neurodevelopmental delay at the neural and cognitive levels. Individuals with elevated impulsivity are at a greater risk to develop behavioral dysregulation over the following two years and may thus require specific early interventions.Competing Interest StatementBJS consults for Cambridge Cognition, Greenfield BioVentures, and Cassava Sciences. TWR consults for Cambridge Cognition, Shionogi, Heptares, Takeda, Arcadia, and Greenfield Bioventures; and receives royalties from Cambridge Cognition and research grants from Shionogi and GlaxoSmithKline. All other authors report no biomedical financial interests or potential conflicts of interest.Funding StatementJZ was supported by Shanghai Municipal Science and Technology Major Project (No.2018SHZDZX01) and ZJLab and NSFC 61973086. JF was supported by the 111 Project (No. B18015), the key project of Shanghai Science and Technology (No. 16JC1420402), National Key R&D Program of China (No. 2018YFC1312900), National Natural Science Foundation of China (NSFC 91630314). BB is supported by the National Key Research and Development Program of China (2018YFA0701400).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data, which can be obtained from: https://nda.nih.gov/study.html?id=901I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://nda.nih.gov/study.html?id=901 https://nda.nih.gov/study.html?id=901